Day 1 – Tuesday, 16 September 2025Tuesday, September 16, 2025 - ET (Eastern Time, GMT-05:00)

What does a truly diverse and equitable biopharma industry look like in 2025? Industry leaders will share insights on the importance of cultivating a workplace that values different backgrounds, experiences, and perspectives while ensuring fair access to opportunities for growth and leadership. This discussion will highlight the business and ethical advantages of fostering a workforce that reflects the broad talent pool available. Panelists will explore practical strategies for breaking down barriers, supporting career advancement, and creating an environment where all employees can thrive.

• The business case for broadening representation and advancing equity in biopharma
• Strategies for creating an environment where talent is recognized and rewarded equitably
• Effective programs and best practices for expanding access to opportunities
• The role of leadership in driving meaningful change and fostering a dynamic workforce

The start of 2025 saw the biopharma M&A landscape marked by both optimism and uncertainty. After a slow-down in 2024, driven by a mix of economic pressures, regulatory scrutiny, and shifting market dynamics, the industry is poised for a potential recovery. However, with continuing looming patent cliffs, increasing innovation from emerging biotech, and a more cautious regulatory environment, M&A activity is expected to remain measured. Join us as we explore the factors shaping pharma’s M&A strategies, the impact of global geopolitical tensions, and where the biggest opportunities lie for dealmakers this year.

• M&A fundamentals in 2025: the balance between a strong deal capacity and a cautious regulatory environment
• Patent cliff pressures and the hunt for innovation - how big pharma is navigating its revenue replenishment strategy
• Early-stage vs. commercial-stage deals: what trends will dominate and where are the opportunities?
• Geopolitical risks, health policy changes, and their influence on cross-border deals and the pharma market